AML cell lines harboring various genetic lesions were tested, these include OCI-AML3 (carries NPM1 and DNMT3AR882C mutations), MOLM-13 (carries FLT3-ITD and KMT2A-MLLT3), and MV4–11 (carries FLT3-ITD and KMT2A-AFF1), aiming to encompass stratification of major risk profiles according to the European LeukemiaNet recommendations50. The gene discussed is RUNX2; the disease is acute myeloid leukemia.